Skip to Main
COVID-19 Protection Study Banner
 

COVID-19 Protection Study

INTERNAL MEDICINE CLINICAL RESEARCH

COVID-19 Protection Study

We are conducting a research study to determine whether an experimental drug can prevent COVID-19 in people who have been exposed to the virus.

If you were recently exposed to someone with COVID-19, you may be eligible to participate in this study.
Contact us now to see if you're eligible—call or text 310-740-4828 or email today.

Participants

  • Why Should Someone Participate in this Study?
    • The study drug could potentially protect individuals and the people they are exposed to (family, friends, and colleagues) from acquiring severe COVID-19. No FDA-approved alternative exists.
    • Participants will be compensated up to $200 for completing all study procedures.
    • The study will advance knowledge on a promising antiviral against COVID-19.
  • Requirements for Study Participants
    • Adults ages 18-65
    • Must have been exposed to a person who has tested positive for COVID-19 within the last four days (96 hours)
    • Must have no major medical problems with the heart, liver, gut and kidneys
    • Must not be pregnant or breastfeeding
  • Study Details
    • Participants will be randomly assigned to take the study drug or a placebo for seven days.
    • Participants will be tested for COVID-19 up to four times.
    • Participants will be asked to answer questions about any symptoms.

Research Team

Dr. Theodoros Kelesidis, wearing a light blue shirt and white lab coat standing in the Clements University Hospital lobby

Theodoros Kelesidis, M.D., Ph.D.

Associate Professor of Internal Medicine

Division of Infectious Diseases and Geographic Medicine

a pattern of blue and white

Monisha Kandala

Clinical Researcher/Study Coordinator

a pattern of blue and white

Kamilla Ablyazova

Researcher/Study Coordinator

  • Related Publications
  • Additional Information
    • If you don't get COVID-19, you won't experience the chronic complications after COVID infection, called "long COVID."
    • Even though fewer people are getting very sick or dying from COVID-19, the risk of getting long COVID is still high. At the start of the pandemic, about 10 percent of people who got a COVID-19 infection ended up with long COVID. Now, the risk is less than 4 percent for people who have been vaccinated. This is a big drop, but millions of Americans are still getting COVID-19 every month.
    • Using treatments right after being around someone with COVID-19 might help stop the spread and lower the number of COVID-19 cases.
    • The experimental drug in this study is safe and easily accessible (see our publication), but studies such as this one are needed to determine whether it is also effective in preventing people from acquiring COVID-19.
  • About the Research Team

    The Kelesidis research lab studies immunopathogenesis of viral infections and associated end-organ disease. We aim to understand the crosstalk between viruses and humans and how the viruses contribute to developing end-organ diseases (such as cardiometabolic, brain, liver, and lung diseases). Our ultimate goal is to develop therapies for clinical translation. Our current work focuses on inflammation, oxidative stress, immune dysfunction and developing novel antioxidant and anti-inflammatory therapeutic modalities for cell/tissue damage associated with infections such as chronic HIV infection and respiratory viral infections (such as SARS-CoV-2 infection).

Contact Us

Theodoros.Kelesidis@UTSouthwestern.edu
Call or text: 310-740-4828

Physical Address
Department of Internal Medicine
5959 Harry Hines Blvd.
Dallas, TX 75390

Back-to top